In that prospect, there is a body of evidence that fetuin-A could serve as new molecular target in the elucidation of complex pathophysiological pathways involved in the onset of metabolic disorders, and could also be used as a useful marker in clinical practice in the future for the early diagnosis of these conditions. This evidence concerns the gene AHSG and metabolic disease.